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AbstrAct
Objective
To determine the most effective interventions in 
recently detoxified, alcohol dependent patients for 
implementation in primary care.
Design
Systematic review and network meta-analysis.
Data sOurces
Medline, Embase, PsycINFO, Cochrane CENTRAL, 
ClinicalTrials.gov, and the World Health Organization’s 
International Clinical Trials Registry Platform.
stuDy selectiOn
Randomised controlled trials comparing two or more 
interventions that could be used in primary care. The 
population was patients with alcohol dependency 
diagnosed by standardised clinical tools and who 
became detoxified within four weeks.
Data extractiOn
Outcomes of interest were continuous abstinence 
from alcohol (effectiveness) and all cause dropouts 
(as a proxy for acceptability) at least 12 weeks after 
start of intervention.
results
64 trials (43 interventions) were included. The 
median probability of abstinence across placebo 
arms was 25%. Compared with placebo, the only 
intervention associated with increased probability 
of abstinence and moderate certainty evidence was 
acamprosate (odds ratio 1.86, 95% confidence 
interval 1.49 to 2.33, corresponding to an absolute 
probability of 38%). Of the 62 included trials that 
reported all cause dropouts, interventions associated 
with a reduced number of dropouts compared with 
placebo (probability 50%) and moderate certainty 
of evidence were acamprosate (0.73, 0.62 to 0.86; 
42%), naltrexone (0.70, 0.50 to 0.98; 41%), and 
acamprosate-naltrexone (0.30, 0.13 to 0.67; 17%). 
Acamprosate was the only intervention associated 
with moderate confidence in the evidence of 
effectiveness and acceptability up to 12 months. It 
is uncertain whether other interventions can help 
maintain abstinence and reduce dropouts because of 
low confidence in the evidence.
cOnclusiOns
Evidence is lacking for benefit from interventions that 
could be implemented in primary care settings for 
alcohol abstinence, other than for acamprosate. More 
evidence from high quality randomised controlled 
trials is needed, as are strategies using combined 
interventions (combinations of drug interventions 
or drug and psychosocial interventions) to improve 




In the United Kingdom, the morbidity and mortality 
burden from alcohol consumption remains high, with 
7% of hospital admissions related to alcohol.1 Liver 
disease is the third most common cause of premature 
death in the UK and the only major cause of death that 
is on the increase, with about two thirds of such deaths 
related to alcohol.2 Alcohol related harm is estimated 
to cost the UK National Health Service £3.5bn ($4.5bn; 
€3.9bn) annually, with the total annual cost to the UK 
estimated at £21bn.1 3
In England, around more than half a million adults 
are alcohol dependent and need assessment and 
treatment.4 However, only one in four of those with 
alcohol dependence seek treatment, and relapse is 
common.5 The National Institute for Health and Care 
Excellence guideline6 recommends a comprehensive 
assessment, followed by either community based or 
residential medically assisted alcohol withdrawal, 
and that in particular drug treatments for abstinence 
should be considered by specialist staff for patients 
with moderate to severe alcohol dependence. The 
capacity to offer this level of support in specialist 
services for the number of patients who need such 
care is, however, limited; about 82% of people do not 
receive the specialist treatment needed.7 Switching the 
management of alcohol dependence to within primary 
care has the potential to improve access to treatment. 
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WhAt Is AlreAdy knoWn on thIs topIc
A considerable need exists for the management of patients with alcohol 
dependence that cannot be met by specialist services alone but only through 
expanding treatment in primary care
This is not yet reflected in UK clinical guidance
Current evidence is generally based on single or specific interventions with broad 
inclusion criteria and mixed outcomes in patients with alcohol dependency
WhAt thIs study Adds
Acamprosate was the only intervention with enough evidence of benefit 
for maintaining alcohol abstinence and acceptability up to 12 months after 
detoxification in primary care settings
The quality of evidence was mostly low and most of the evidence was derived 
from single, small trials
More evidence from high quality randomised controlled trials is therefore needed 
on the best interventions in primary care to inform clinical treatment and enable 
patient access
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Here we consider primary care to be a setting where 
medical services were provided in general practice, the 
first point of contact for patients, and not by specialist 
services.8 To achieve better long term outcomes, the 
maintenance of abstinence needs to be followed by 
medium to long term support. Although such support 
is currently managed by specialist care, primary care 
stands in a unique position to provide holistic care.
Evidence is accumulating for several interventions 
to maintain abstinence that feasibly could be offered 
in primary care, or at the level of a close collaboration 
between primary and specialist care.9 In this systema­
tic review and network meta­analysis we aimed to 
determine the most effective interventions for alcohol 
abstinence with the potential to be delivered in a 
primary care setting.
Methods
The protocol for this review has been published 
previously10 and registered in the International Pro­
spective Register of Systematic Reviews (PROSPERO 
2016: CRD42016049779). This report complies with 
the PRISMA (preferred reporting items for systematic 
reviews and meta­analyses) network meta­analysis 
extension statement (see supplement 1 for checklist).11
eligibility criteria
We sought randomised controlled trials that investi­
gated any treatment intervention (drug, psychological, 
or both) for maintaining abstinence in recently 
detoxified, alcohol dependent adults. We were 
interested only in interventions appropriate for pri­
mary care settings and only drugs that are available 
in the UK. Studies were eligible if the participants 
were older than 18 years with alcohol dependency 
diagnosed using standardised diagnostic criteria (eg, 
Diagnostic and Statistical Manual of Mental Disorders, 
International Classification of Diseases) or the Alcohol 
Use Disorders Identification Test (AUDIT; score ≥20). 
To reflect current clinical practice, we sought only 
studies that provided detoxification to participants, 
as well as studies that recruited participants who had 
undergone detoxification less than four weeks before 
randomisation. To be eligible, studies had to have 
follow­up periods longer than 12 weeks.
Outcomes
Our primary effectiveness outcome was continuous 
abstinence as reported by the trial authors. We chose 
abstinence over reduced risk drinking as the most 
appropriate outcome for this population of alcohol 
dependent patients because abstinence was the 
preferred goal among patients in a recent large UK 
trial12 and NICE guideline6 and because abstainers 
have a lower rate of relapse over the longer term.13 14 
For secondary outcomes, we sought data on amount of 
alcohol consumption, drinking frequency, intervention 
compliance, adverse events, and withdrawal from 
the study. These were reported inconsistently and 
were not amenable to meaningful analysis. Since 
we were generally interested in acceptability of the 
interventions, we used the number of dropouts (or 
number lost to follow­up) for any reason as a proxy for 
acceptability, as a secondary outcome.
search strategy
An information specialist (SD) developed the search 
strategies and searched four electronic databases: 
Cochrane Central Register of Controlled Trials 
(CENTRAL), Ovid Medline, Ovid Embase, and Ovid 
PsycINFO from inception date to 3 March 2020 (see 
supplement 2 for search strategies). To supplement the 
search of the electronic databases we additionally hand 
searched relevant randomised controlled trials from 
reference lists of identified systematic reviews, meta­
analyses, and studies included in this review (known 
as snowballing15). Two trial registries, ClinicalTrials.
gov and WHO International Clinical Trials Registry 
Platform (ICTRP), were searched from inception date 
to March 2020 to identify registered trials and relevant 
reports. No restriction was applied on date, language, 
or publication status.
selection of studies
Search results were managed using Endnote and 
Microsoft Excel. One author (HC) screened the titles 
and abstracts of all identified references. A second 
reviewer (RGE, LAM, SD, AT, or GJM) also independently 
screened the titles and abstracts identified from 
the primary source of randomised controlled trials 
(CENTRAL), comprising more than half of the search 
results. The main screener missed none of the studies 
eventually included in the review, indicating a low 
likelihood that trials were missed in the other sources. 
The full texts of potentially eligible references were 
obtained and screened independently in duplicate 
(by HC and one of RGE, LAM, SD, AT, or GJM). A native 
speaker assessed or translated studies in non­English 
languages. Disagreements when screening the title, 
abstract, and full text were resolved by discussion.
To determine interventions that are applicable to 
primary care,8 three content experts (DK, ALH, and 
MH) examined the interventions. Interventions that 
involved frequent, repeated intravenous infusions, 
uncommon equipment in primary care, illicit drugs, 
experimental chemicals, and drugs unlicensed in 
the UK were not included in the review (see list in 
supplement 3). We excluded studies on pregnant 
women, participants with chronic liver disease, 
participants with HIV/AIDS, and patients with liver 
transplant owing to the specific clinical considerations 
of these populations.
Data extraction
Data from each eligible study were extracted in 
duplicate using pre­piloted, standardised Microsoft 
Excel spreadsheets. When multiple publications from 
one study existed, we considered and combined all 
publications to extract information, so that a single 
result from each study contributed to each synthesis. In 
the case of missing data, we contacted authors directly, 
and when no response was received, we attempted to 
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retrieve information from other systematic reviews and 
meta­analyses. For example, the number of patients 
in each group in Pelc et al16 was informed using the 
review by Mann et al.17
risk of bias assessment
A pre­release version of the RoB 2 tool was used to 
assess the risk of bias in five domains of the randomised 
trials18: bias arising from the randomisation process, 
deviations from intended interventions, missing 
outcome data, measurement of the outcome, and 
selection of the reported result. Domain level 
judgments led to an overall risk of bias judgment 
for each study result. Two reviewers (LAM, RGE, 
GJM, and AM paired with HC) assessed each study 
independently. Discrepancies between reviewers were 
resolved by discussion.
Quality of evidence evaluation
Confidence in the evidence was evaluated using an 
adapted version of GRADE (grading recommenda­
tions assessment, development and evaluation) 
methodology19 through a web based application, 
Confidence In Network Meta­Analysis (CINeMA).20 
Content experts (MH and DK), in conjunction with 
HC, AM, and JPTH, evaluated the evidence in each 
intervention comparison based on within study bias, 
reporting bias, indirectness, imprecision, hetero­
geneity, and incoherence. Supplement 4 shows the 
criteria for the GRADE assessment using CINeMA. Risk 
of reporting bias was informed by considering non­
statistical factors (empirical knowledge from searches, 
screening, and communications with expert and study 
authors) and using funnel plots (if >10 studies in 
pairwise comparisons and comparison adjusted funnel 
plots for network meta­analysis).21 22
Data synthesis and analyses
We grouped different dosages of the same interventions 
into one node for network meta­analyses. For one 
study,23 we grouped disulfiram (1 mg/day) with the 
placebo (riboflavin) group because the author used the 
disulfiram group as a control and indicated no reaction 
between disulfiram and ethanol at this low dose. We 
coded citalopram and escitalopram as the same node 
in the network meta­analysis because these two drugs 
are clinically interchangeable; and the dosage and 
regimen used in studies that investigated these drugs 
were aligned with clinical practice. This allowed us to 
incorporate one study that would otherwise have been 
excluded.24 A variety of control groups were observed 
among the included studies. We categorised these 
control groups into placebo or treatment as usual. 
Placebo groups followed the conventional definition, 
suggesting a physical pill without the active ingredient 
or ingredients. Treatment as usual groups consisted 
of standard, conventional treatments and 12 step 
facilitation.
The primary outcome measure was dichotomous, 
ideally extracted as the number of patients who 
remained abstinent (no alcohol intake) after 
randomisation, out of the total number of participants 
randomised. We converted percentages or fractions to 
whole numbers based on the number of randomised 
patients, provided an intention­to­treat analysis 
had been used. If intention­to­treat results were not 
available, we used reported results for completers. A 
similar approach was used for dropouts, defined as the 
number of patients who withdrew from the study at 
reported time points.
We found that outcomes were reported over a wide 
range of time points between three and 24 months. 
We categorised outcomes (in a slight change from the 
protocol10) into short (3­6 months), medium (6­12 
months), and long (12­24 months) term outcomes. 
If a trial reported results at multiple time points, we 
extracted the result at the longest time point within 
these periods for the main analysis. To enable all 
studies to be included, in the main analysis we 
combined results reported at the nearest time point to 
12 months from each study.
We conducted pairwise and network meta­analyses 
for effectiveness (abstinence) and acceptability 
(dropouts). We reported estimated odd ratios with 95% 
confidence intervals comparing each intervention with 
placebo or with treatment as usual depending on the 
network structure. Heterogeneity was assessed using 
the results of the pairwise analyses, and between 
study variance for the network meta­analyses (τ2). To 
compute absolute probabilities of each outcome under 
each treatment, we took the median probability on 
placebo across all trials in the main analysis (rounded 
to the nearest multiple of 5) and applied the odds ratio 
for each treatment to this probability.25 For evaluations 
of consistency in the network, we used the design­by­
treatment interaction model26 (global assessment) and 
node split27 (local assessment) methods. We used the 
mean of the distribution of ranks for each intervention 
to present its relative order of preference based on the 
network meta­analysis.
All analyses were performed in STATA MP15, 
assuming random effects for intervention effects and 
fixed effects for study baselines within a frequentist 
framework.22 28 Networks were plotted using Gephi 
(version 0.9.2).29 The dataset used for computing the 
analyses is available in the data.bris repository.
additional analyses
Separate network meta­analyses by intervention types 
(psychosocial interventions, drug, or combined drug 
interventions) were conducted to check the robustness 
of results to the possibility that treatment effects were 
not transitive across different approaches of studies to 
intervention. We also conducted analyses separately 
for outcomes measured at short, medium, and long 
term time points. We had planned sensitivity analyses 
that excluded studies with overall high risk of bias but 
did not do these owing to sparsity of data.
We were unable to conduct several preplanned 
subgroup and meta­regression analyses (length of 
intervention, optional psychosocial interventions, 
dosing and schedule of interventions, psychiatric 
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comorbidity, severity of alcohol dependence, and 
social background) because of inconsistent or poorly 
reported data on these characteristics across studies. 
Several study level characteristics were investigated 
to explore heterogeneity of intervention effects across 
intervention comparisons: percentage of female 
populations, mean age, methods of detoxification 
(medically assisted detoxification or unclear), 
settings of detoxification (inpatient, outpatient, 
mixed, or unclear), and continent of study sites (five 
continents).
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked 
to advise on interpretation or writing up of the results. 
We do plan to disseminate the results of the research to 
the relevant patient communities.
results
Overall, 29 323 records were identified from electronic 
databases and 2378 from other sources. After 
removing 11 880 duplicates, the titles and abstracts of 
the 19 821 remaining records were screened. Overall, 
18 601 records were irrelevant based on the titles and 
abstracts, thus full texts were sought for the remaining 
1220 records. One hundred and two studies (143 
references) met the inclusion criteria (fig 1). One study 
was excluded because the trial compared the effects 
of oxcarbazepine in two different dosages.30 Results 
for continuous abstinence were available (either from 
reports or by contacting trial authors) for 64 studies 
(reported in 99 references), and these were included in 
the review. Full lists of excluded studies and reasons 
for exclusion are available in the data.bris repository 
(https://data.bris.ac.uk/data/).
Overview of studies
Supplement 5 shows the characteristics of the 64 
included studies. These were published over a 
period of 35 years (1986­2020). In all but one study, 
participants started the trial after detoxification; in 
the remaining study the intervention was started 
during detoxification.31 The methods and settings of 
detoxification were poorly reported (table 1). Most 
studies stated only that patients were detoxified, without 
specifying the details. In studies that did report the 
methods of medically assisted detoxification, patients 
were commonly detoxified with benzodiazepines, 
with a third study reporting inpatient detoxification. 
Despite variation in inclusion and exclusion criteria, 
the characteristics of participants were similar across 
studies: predominantly men, aged around 40, and 
presenting with mild to moderate mental illness, such 
as anxiety and depression. Only four studies recruited 
specific populations: people with depression32 33 or 
sleep disturbance,34 elderly people,35 and women.36 No 
information was provided on the use of existing drugs 
or additional drugs in most trials; and if provided, 
patients were usually not allowed to use or had limited 
use of additional antidepressants, anticonvulsants, 
anxiolytics, and hypnotics during the trials.
Drug interventions were the most studied type of 
intervention (51/64 studies) (table 1). Six studies 
investigated seven forms of psychosocial interven­
tions: Addiction­Comprehensive Health Enhancement 
Support System,37 cognitive behavioural therapy,38­40 
short form cognitive behavioural therapy,41 contin­
gency management,42 coping skill training,38­40 home 
visit,42 43 and motivational enhancement therapy.40 41 
These interventions were applied either on top of an 
existing treatment programme37 43 or alone.38­40 Two 
studies specifically investigated combinations of drug 
and psychosocial interventions: one study compared 
the effect of combined follow­up by a community 
nurse and acamprosate with acamprosate alone44; 
another compared the effects of combined treatment 
with nefazodone and cognitive behavioural therapy.45 
In most studies, patients received concomitant 
psychosocial therapy or were encouraged to attend 
self­help interventions, or both, such as Alcoholics 
Anonymous and social services. However, details of 
these concomitant interventions, such as settings, 
methods, and attendance rates, were poorly reported, 
therefore further analyses of these factors were not 
possible.
risk of bias within included studies
Supplement 6 shows the results of risk of bias 
assessments for the outcome abstinence. Overall, 
30 and 27 out of 64 studies were judged overall 
to have “some concerns” or to be at “high risk” of 
bias, respectively. The main reasons for having some 
concerns were lack of description in the randomisation 
process (39/64 studies) and unbalanced missing data 
between groups (13/64 studies); and the main reason 
for high risk of bias (20/64 studies) was missing 
outcome data. Treatment effects of some studies could 
be contaminated owing to the open label design or the 
nature of interventions. These contributed to high risk 
of bias owing to deviations from intended interventions 
in two trials.
effectiveness: maintaining abstinence up to 12 
months versus placebo
Sixty four studies (43 interventions) were included in 
the network meta­analysis of the primary outcome (fig 
2). Placebo was the most used control (42/64 studies). 
Heterogeneity was low or undetectable in most of 
the separate pairwise comparisons because of the 
low number of studies involved in each comparison. 
The estimated between study variance (τ2) from the 
network meta­analysis was 0.084 (see supplement 
7). No evidence of inconsistency based on a random 
effects design­by­treatment interaction model was 
found (χ2=16.19, df=13, P=0.24). Local tests of 
loop inconsistency did not indicate inconsistency 
between direct and indirect estimations, except 
for one comparison between sodium oxybate (also 
known as sodium salt of gamma hydroxybutyric 
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acid or GHB) and placebo (P=0.042), which is 
compatible with chance given the large number of 
comparisons.
Table 2 shows the main results of the analysis, 
along with assessments of the quality of evidence 
for each intervention. The median probability of 
staying abstinent across placebo arms was 25%. Most 
interventions showed no or insufficient evidence of an 
effect on maintaining abstinence greater than placebo. 
Drug interventions had mixed results, with estimated 
odds ratios ranging from 0.31 (95% confidence 
interval 0.11 to 0.87) for galantamine (indicating 
reduced probability of abstinence compared with 
placebo) to increased odds of abstinence compared 
with placebo for four interventions: acamprosate 
(1.86, 1.49 to 2.33), topiramate (1.88, 1.06 to 3.34), 
sodium oxybate (2.31, 1.22 to 4.36), and quetiapine 
(6.75, 1.20 to 38.05). Other drugs licensed for treating 
alcohol dependence, disulfiram (0.93, 0.48 to 1.79) 
and naltrexone (1.36, 0.97 to 1.91), were not or were 
weakly associated with improved abstinence. All 
psychosocial interventions alone were not associated 
with a greater probability of maintaining abstinence 
up to 12 months. Four combined interventions were 
more effective than placebo at maintaining abstinence: 
acamprosate and nurse visits (4.59, 1.47 to 14.36), 
acamprosate and naltrexone (3.68, 1.50 to 9.02), 
sodium oxybate and naltrexone (12.64, 2.77 to 57.78), 
and naltrexone and sodium oxybate and escitalopram 
(25.65, 2.13 to 309.46). Treatment as usual (0.52, 
0.29 to 0.94), flupenthixol (0.44, 0.20 to 0.95), and 
galantamine 0.31 (0.11 to 0.87) were associated 
with reduced odds of relapse compared with placebo. 
However, confidence in the evidence of the effect 
of most interventions, apart from acamprosate and 
tiapride, was low or very low. The reasons for the 
low to very low confidence were within study bias, 
imprecision, and heterogeneity, mainly because the 
evidence for most interventions was generated from 
single, small studies. 
Additional references















References identified through database searching
References excluded by titles or abstracts
Full text articles assessed for eligibility
Studies meeting criteria (143 references)










Studies excluded (44 references)
Studies without primary outcome




8204   Embase 6200   PsycINFO 519   From reference lists 1038   WHO ICTRP
821   ClinicalTrials.gov
38
64
Fig 1 | study selection flowchart
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Secondary outcome: all cause dropouts up to 12 
months versus placebo
The composition of studies reporting all cause 
dropouts was similar to that for the primary outcome. 
Sixty two studies (43 interventions) were included in 
the network meta­analysis of the secondary outcome 
(fig 3). Heterogeneity in the comparisons was low or 
non­detectable owing to low number of studies within 
the comparisons (see supplement 7). The estimated 
between study variance (τ2) from the network meta­
analysis was 0.031. No evidence of inconsistency 
was found in the random effects design­by­treatment 
interaction model (χ2=12.95, df=12, P=0.37) or when 
using the node split method.
Table 3 shows the results of the network meta­
analysis and confidence in the evidence. The median 
probability of dropout across placebo arms was 48%, 
although for interpretational convenience we set it 
at 50% for computation of corresponding absolute 
risks for each intervention. Compared with placebo, 
the relative treatment effects of active interventions 
on reducing dropouts were similar. Only a few 
interventions were associated with reduced dropouts 
compared with placebo: acamprosate (odds ratio 0.73, 
95% confidence interval 0.62 to 0.86), naltrexone 
(0.70, 0.50 to 0.98), topiramate (0.45, 0.24 to 0.83), 
home visits (0.32, 0.11 to 0.95), short form cognitive 
behavioural therapy (0.06, 0.01 to 0.33), acamprosate 
and nurse visits (0.21, 0.07 to 0.57), and acamprosate 
and naltrexone (0.30, 0.13 to 0.67). Flupenthixol 
(2.37, 1.27 to 4.40), fluvoxamine (2.15, 1.30 to 3.55), 
and carbamazepine (12.00, 1.22 to 118.42) were 
associated with increased odds of dropout compared 
with placebo. Confidence in the evidence on the effect 
of interventions was also generally low or very low, with 
four exceptions as moderate (acamprosate, naltrexone, 
tiapride, and acamprosate and naltrexone).
clustered rank of treatments
The mean rank of each treatment was plotted to 
illustrate clustering of interventions according to 
higher effectiveness (maintaining abstinence) and 
higher acceptability (reducing dropout), as well as 
illustrating the corresponding confidence in the 
evidence (fig 4). Although many interventions cluster 
in the lower left hand corner of the figure (indicating 
higher rank on both outcomes than placebo), the low 
or very low confidence in the evidence limited the 
credibility of all interventions except for acamprosate.
results of additional analysis
Additional network meta­analysis stratified by inter­
vention types did not show significant differences 
in the relative intervention effects (supplement 
8). No evidence was found of heterogeneity being 
explained by meta­regression on predefined study 
level characteristics, although this was limited by the 
number of studies in each intervention and the quality 
of reporting. Only eight studies (seven interventions) 
had results for the long term analysis. Acamprosate 
was the only intervention associated with improved 
maintenance of abstinence compared with placebo 
(odds ratio 1.49, 95% confidence interval 0.82 to 
2.71), although the evidence is weak.
discussion
Acamprosate is the only intervention with enough 
evidence to conclude that it is better than placebo in 
supporting detoxified, alcohol dependent patients 
to maintain abstinence for up to 12 months in 
primary care settings. Weak evidence suggested that 
acamprosate might be effective in the longer term. It 
is uncertain whether the other current licensed drugs, 
naltrexone and disulfiram, improve abstinence in such 
patients. Although other interventions, such as sodium 
oxybate, pregabalin, topiramate, and combinations 
of other interventions, such as acamprosate and 
naltrexone, acamprosate and nurse visits, and sodium 
oxybate and naltrexone, may lead to better outcomes 
than placebo, the low numbers of studies and patients 
reduced our confidence in the evidence.
strengths and limitations of this review
Our research question and study eligibility criteria 
were designed to align with current practice to bridge 
the evidence gap in the care pathway of recently 
detoxified, alcohol dependent patients in a primary 
care setting. A main strength of our study is the 
sensitive search strategies and snowballing technique 
used to retrieve potentially eligible studies. These were 
table 1 | general characteristics of studies. values are numbers (percentages) unless 
stated otherwise
characteristics abstinence (n=64) all cause dropouts (n=62)
study characteristics
Median (range) study sample size 106 (17-774) 115 (17-774)
No of arms:
 2 55 (86) 53 (85)
 3 6 (9) 6 (10)
 4 3 (5) 3 (5)
Type of controls:
 Placebo 42 (68) 41 (68)
 Treatment as usual 9 (14) 9 (15)
No of interventions 43 43
Type of interventions:
 Drug 51 (80) 49 (79)
 Psychosocial 6 (9) 6 (10)
 Combined 7 (11) 7 (11)
Median (range) follow-up (days) 180 (84-365) 180 (84-365)
Continent:
 North America 12 (19) 12 (19)
 Europe 46 (72) 44 (71)
 Asia 3 (5) 3 (5)
 South America 3 (5) 3 (5)
Patient characteristics
Median (range) age (years); No in group 43.2 (30.6-63.4); n=61 43 (30.6-63.4); n=59
Median (range) women (%); No in group 22 (0-100); n=59 22 (0-100); n=58
Detoxification methods:
 Drug 20 (31) 20 (32)
 Unclear 44 (70) 42 (68)
Detoxification settings:
 Inpatient 20 (31) 20 (32)
 Outpatient 2 (3) 2 (3)
 Mixed 7 (11) 7 (11)
 Unclear 35 (55) 33 (53)
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required because the titles, abstracts, and indexes of 
many studies do not contain keywords or are poorly 
indexed. We also included all available interventions 
suitable for primary care to provide an extensive list as 
a reference for clinical practice.
Our review also has limitations. Firstly, we 
focused on the maintenance of abstinence. While 
this is of direct relevance to clinical practice and 
service planning, it means we excluded studies 
that investigated the effect of interventions in 
reducing alcohol consumption in alcohol dependent 
people who are still drinking (eg, nalmefene46 and 
topiramate46) rather than maintaining abstinence. 
Previous reviews of interventions in abstinent alcohol 
dependence (ie, post­detoxification) have reported 
evidence of naltrexone47­49 in preventing relapse 
from a lapse, and for acamprosate48 50 or disulfiram51 
in maintaining abstinence in patients with alcohol 
dependence. These three drugs are recommended by 
NICE6 for clinical effectiveness, and choice is tailored 
depending on the drinking behaviour and clinical 
situation of a patient. It remains unclear which method 
of achieving abstinence is more effective for patients 
with severe alcohol dependency, detoxification or 
gradual weaning. A shared decision on the treatment 
goal should be discussed and made between a patient 
and a prescriber. Secondly, definitions of detoxification 
were ambiguous and poorly reported across studies, 
meaning that we might have included studies when 
participants were not truly detoxified and missed 
studies when participants were detoxified but not 
described as such. Although we tried to contact study 
authors to confirm whether participants were detoxified 
















































Fig 2 | network plots for alcohol abstinence in relation to treatment for alcohol dependency. the size of circles 
is proportional to the number of randomised patients and the width of lines is proportional to the number 
of studies in each direct comparison. a-cHess=addiction-comprehensive Health enhancement support 
system; acP=acamprosate; acP+ntx=acamprosate+naltrexone; acP+nus=acamprosate+nurse visits; 
cbt=cognitive behavioural therapy; cbZ=carbamazepine; cit/est=citalopram or escitalopram; cst=coping 
skill training; est+gHb=escitalopram+sodium salt of gamma hydroxybutyric acid (sodium oxybate); 
est+ntx=escitalopram+naltrexone; est+ntx+gHb=escitalopram+naltrexone+sodium oxybate; gHb=sodium 
oxybate; gla=galantamine; HOv=home visit; met=motivational enhancement therapy; ntx=naltrexone; 
ntx+gHb=naltrexone+sodium oxybate; tau=treatment as usual
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in earlier published studies. Additionally, this (similar 
to inconsistent reporting in socioeconomic data 
and characteristics of participants) limited us in the 
performance of additional analysis in how subsets of 
particular patients respond to an intervention. Thirdly, 
the use of all cause dropout as a proxy for acceptability 
was driven primarily by practical considerations 
because dropouts often occur in these patients and 
are well reported across studies. Other outcomes 
should be taken into account to draw firm conclusions 
about acceptability of the interventions.52 Finally, 
most included studies were conducted in the United 
States and Europe, which could have implications for 
applicability to the UK setting. We excluded studies 
conducted in hospital and intensive rehabilitation 
settings to give a comprehensive overview of available 
interventions that could be considered in primary 
care settings. The translation of evidence into practice 
still requires thorough evaluation among patients, 
practitioners, policymakers, and stakeholders, 
table 2 | network meta-analysis (nma) and quality of evidence for abstinence
intervention  
(reference: placebo)
no of arms 
(placebo, 
n=42)




Odd ratios (95% ci) corresponding 
absolute probability 
of abstinence (95% 
ci) (assumed 25% for 
placebo) (%)
Quality of  
evidence*Direct estimate indirect estimate nma estimate
Psychosocial interventions
Treatment as usual 9 800 - 0.52 (0.29 to 0.94) 0.52 (0.29 to 0.94) 15 (9 to 24) Low†‡§¶
A-CHESS 1 170 - 0.88 (0.35 to 2.21) 0.88 (0.35 to 2.21) 23 (10 to 42) Very low†‡§¶
CBT 2 306 - 0.53 (0.23 to 1.22) 0.53 (0.23 to 1.22) 15 (7 to 29) Low†§¶
Short form CBT 1 43 - 0.05 (0.00 to 1.16) 0.05 (0.00 to 1.16) 2 (0 to 28) Very low†§¶
Contingency management 1 79 - 0.78 (0.17 to 3.61) 0.78 (0.17 to 3.61) 21 (5 to 55) Low†‡§
Coping skill training 1 40 - 0.35 (0.10 to 1.19) 0.35 (0.10 to 1.19) 10 (3 to 28) Very low†§¶
Home visit 2 142 - 0.95 (0.32 to 2.85) 0.95 (0.32 to 2.85) 24 (10 to 49) Low†§¶
MET 2 308 - 0.45 (0.19 to 1.11) 0.45 (0.19 to 1.11) 13 (6 to 27) Very low†§¶
Drug interventions
Acamprosate 18 2297 1.92 (1.52 to 2.42) 0.74 (0.21 to 2.53) 1.86 (1.49 to 2.33) 38 (33 to 44) Moderate¶**
Amisulpride 1 37 0.39 (0.09 to 1.64) - 0.39 (0.09 to 1.64) 12 (3 to 35) Low†§¶
Aripiprazole 1 29 - 1.49 (0.43 to 5.18) 1.49 (0.43 to 5.18) 33 (12 to 63) Low†§¶
Atenolol 1 50 0.85 (0.25 to 2.95) - 0.85 (0.25 to 2.95) 22 (8 to 50) Very low†‡§¶
Baclofen 1 28 4.63 (1.00 to 21.48) - 4.63 (1.00 to 21.48) 61 (25 to 88) Low†§¶
Carbamazepine 1 13 0.55 (0.08 to 3.90) - 0.55 (0.08 to 3.90) 15 (2 to 57) Very low†‡§¶
Citalopram/escitalopram 2 45 - 1.03 (0.33 to 3.16) 1.03 (0.33 to 3.16) 25 (10 to 51) Low†§¶
Disulfiram 2 221 0.97 (0.46 to 2.01) 0.72 (0.13 to 4.05) 0.93 (0.48 to 1.79) 24 (14 to 37) Low†‡§¶
Fluoxetine 2 50 2.14 (0.48 to 9.52) 4.51 (0.83 to 24.39) 2.97 (0.97 to 9.05) 50 (24 to 75) Very low†‡§¶
Flupenthixol 1 142 0.44 (0.20 to 0.95) - 0.44 (0.20 to 0.95) 13 (6 to 24) Very low†§¶
Fluvoxamine 3 293 0.99 (0.49 to 2.01) 1.14 (0.34 to 3.89) 1.03 (0.57 to 1.88) 26 (16 to 38) Low†§¶
Galantamine 1 74 0.31 (0.11 to 0.87) - 0.31 (0.11 to 0.87) 9 (4 to 23) Low†§¶
GHB 4 201 1.65 (0.85 to 3.24) 7.48 (2.05 to 27.28) 2.31 (1.22 to 4.36) 43 (29 to 59) Very low†‡¶**
Levetiracetam 1 95 1.03 (0.46 to 2.34) - 1.03 (0.46 to 2.34) 26 (13 to 44) Low†§¶
Lisuride 1 57 0.38 (0.13 to 1.12) - 0.38 (0.13 to 1.12) 11 (4 to 27) Very low†§¶
Lithium 1 28 1.43 (0.39 to 5.23) - 1.43 (0.39 to 5.23) 32 (12 to 64) Low†§¶
Modafinil 1 41 2.48 (0.72 to 8.53) - 2.48 (0.72 to 8.53) 45 (19 to 74) Low†§¶
Naltrexone 17 878 1.29 (0.86 to 1.92) 1.59 (0.81 to 3.10) 1.36 (0.97 to 1.91) 31 (24 to 39) Low†§¶
Nefazodone 1 50 0.57 (0.19 to 1.76) - 0.57 (0.19 to 1.76) 16 (6 to 37) Very low†‡§¶
Oxcarbazepine 2 72 - 2.46 (0.91 to 6.61) 2.46 (0.91 to 6.61) 45 (23 to 69) Very low†§¶
Pregabalin 1 31 - 1.97 (0.58 to 6.74) 1.97 (0.58 to 6.74) 40 (16 to 69) Low†§¶
Quetiapine 1 29 6.75 (1.20 to 38.05) - 6.75 (1.20 to 38.05) 69 (29 to 93) Low†§¶
Tianeptine 1 170 1.22 (0.58 to 2.57) - 1.22 (0.58 to 2.57) 29 (16 to 46) Low†§¶
Tiapride 2 187 0.56 (0.30 to 1.05) - 0.56 (0.30 to 1.05) 16 (9 to 26) Moderate§¶
Topiramate 3 194 2.26 (0.83 to 6.13) 1.72 (0.84 to 3.52) 1.88 (1.06 to 3.34) 39 (26 to 53) Very low†‡§¶**
Trazodone 1 88 0.61 (0.20 to 1.84) - 0.61 (0.20 to 1.84) 17 (6 to 38) Very low†‡§¶
combined interventions
Placebo+CBT 1 50 0.83 (0.28 to 2.42) - 0.83 (0.28 to 2.42) 22 (9 to 45) Very low†‡§¶
Nefazodone+CBT 1 53 0.77 (0.26 to 2.23) - 0.77 (0.26 to 2.23) 20 (8 to 43) Very low†‡§¶
Acamprosate+nurse visit 1 50 - 4.59 (1.47 to 14.36) 4.59 (1.47 to 14.36) 60 (33 to 83) Very low a c d
Acamprosate+NTX 1 40 5.57 (1.82 to 16.96) 1.63 (0.33 to 7.95) 3.68 (1.50 to 9.02) 55 (33 to 75) Low†§¶**
GHB+EST 1 12 - 5.13 (0.53 to 49.92) 5.13 (0.53 to 49.92) 63 (15 to 94) Low†§¶
GHB+NTX 1 18 - 12.64 (2.77 to 57.78) 12.64 (2.77 to 57.78) 81 (48 to 95) Very low†‡§¶
NTX+EST 1 12 - 2.57 (0.25 to 25.85) 2.57 (0.25 to 25.85) 46 (8 to 90) Low†§¶
NTX+GHB+EST 1 12 - 25.65 (2.13 to 309.46) 25.65 (2.13 to 309.46) 90 (41 to 99) Low†§¶
A-CHESS=Addiction-Comprehensive Health Enhancement Support System; CBT=cognitive behavioural therapy; MET=motivational enhancement therapy; GHB=sodium salt of gamma 
hydroxybutyric acid (sodium oxybate); EST=escitalopram; NTX=naltrexone.
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which could be aided using knowledge translation 
frameworks.53 54
comparison with other reviews
Our findings agree with previous systematic reviews 
supporting the use of acamprosate in detoxified 
patients with alcohol dependency50 55­57 and are 
in line with recommended guidelines.6 58 Previous 
reviews of interventions to maintain abstinence in 
alcohol dependent patients have mostly focused on a 
single specific intervention or group of interventions, 
and synthesised studies conducted in a variety of 
populations, which makes them less applicable to 
clinical practice. A recent systematic review and 
network meta­analysis,46 which only included five 
interventions, exemplifies this problem. In contrast, 
we included different psychosocial and drug 
interventions that could be implemented in primary 
care using network meta­analysis. One study51 
suggested that disulfiram is effective based on a meta­
analysis of different alcohol drinking outcomes and a 
high heterogeneity of the studies, whereas we found 
limited evidence to support its effect on abstinence 
after evaluating studies using rigorous approaches. Of 
all the drugs studied, disulfiram provides particular 
challenges in placebo controlled blinded trials 
because, compared with the other drugs, patients can 
more easily determine if they are or are not taking 
disulfiram.
conclusions and implications
Most interventions identified in this review were 
not associated with enough evidence to make 
















































Fig 3 | network plots for all cause dropouts in relation to treatment for alcohol dependency. the size of circles 
is proportional to the number of randomised patients and the width of lines is proportional to the number 
of studies in each direct comparison. a-cHess=addiction-comprehensive Health enhancement support 
system; acP=acamprosate; acP+ntx=acamprosate+naltrexone; acP+nus=acamprosate+nurse visits; 
cbt=cognitive behavioural therapy; cbZ=carbamazepine; cit/est=citalopram or escitalopram; cst=coping 
skill training; est+gHb=escitalopram+sodium salt of gamma hydroxybutyric acid (sodium oxybate); 
est+ntx=escitalopram+naltrexone; est+ntx+gHb=escitalopram+naltrexone+sodium oxybate; gHb=sodium 
oxybate; gla=galantamine; HOv=home visit; met=motivational enhancement therapy; ntx=naltrexone; 
ntx+gHb=naltrexone+sodium oxybate; tau=treatment as usual
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are promising and should be investigated in future 
trials. The findings also provide directions for potential 
strategies by including additional interventions to 
complement the treatment effects, such as naltrexone 
or home visits. These could contribute to a pragmatic 
trial design.59 However, the mechanism of acamprosate 
and other interventions on treating alcohol dependence 
remains unclear. Establishing the properties of drugs 
and understanding the psychological needs of alcohol 
dependent patients or the fundamental causes of 
alcohol dependency could also inform new strategies 
for future trial designs.
These findings have important implications for 
clinical practice, as acamprosate was found to be the 
only intervention with enough high quality evidence 
for us to conclude that it is better at maintaining 
alcohol abstinence than placebo. The finding that 
there is currently little evidence on other interventions, 
table 3 | network meta-analysis and quality of evidence for all cause dropouts
intervention  
(reference: placebo)
no of arms 
(placebo, 
n=41)




Odd ratio (95% ci) corresponding absolute 
probability of dropout 
(95% ci) (assumed 50% 
for placebo) (%)
Quality of 
evidenceDirect estimate indirect estimate nma estimate
Psychosocial interventions
Treatment as usual 9 800 - 1.14 (0.65 to 1.99) 1.14 (0.65 to 1.99) 53 (39 to 67) Low†‡§¶
A-CHESS 1 170 - 1.14 (0.50 to 2.60) 1.14 (0.50 to 2.60) 53 (33 to 72) Very low†‡§¶
CBT 2 306 - 1.16 (0.45 to 3.04) 1.16 (0.45 to 3.04) 54 (31 to 75) Low†§¶
Short form CBT 1 43 - 0.06 (0.01 to 0.33) 0.06 (0.01 to 0.33) 6 (1 to 25) Very low†§¶
Contingency management 1 79 - 0.32 (0.02 to 6.55) 0.32 (0.02 to 6.55) 24 (2 to 87) Low†‡§
Coping skill training 1 40 - 1.98 (0.55 to 7.17) 1.98 (0.55 to 7.17) 66 (35 to 88) Low†§¶
Home visit 2 142 - 0.32 (0.11 to 0.95) 0.32 (0.11 to 0.95) 24 (10 to 49) Low†§¶
MET 2 308 - 1.30 (0.46 to 3.64) 1.30 (0.46 to 3.64) 56 (32 to 78) Low†§¶
Drug interventions
Acamprosate 17 2268 0.71 (0.58 to 0.87) 1.17 (0.31 to 4.34) 0.73 (0.62 to 0.86) 42 (38 to 46) Moderate§**
Amisulpride 1 37 1.89 (0.66 to 5.43) - 1.89 (0.66 to 5.43) 65 (40 to 84) Low†§¶
Aripiprazole 1 29 - 0.67 (0.18 to 2.45) 0.67 (0.18 to 2.45) 40 (15 to 71) Low†§¶
Atenolol 1 50 1.09 (0.46 to 2.57) - 1.09 (0.46 to 2.57) 52 (31 to 72) Low†‡§¶
Baclofen 1 28 0.87 (0.29 to 2.62) - 0.87 (0.29 to 2.62) 46 (22 to 72) Low†§¶
Carbamazepine 1 13 12.00  
(1.22 to 118.42)
- 12.00  
(1.22 to 118.42)
92 (55 to 99) Very low†‡§¶
Citalopram/escitalopram 2 45 - 3.24 (0.73 to 14.40) 3.24 (0.73 to 14.40) 76 (42 to 94) Low†§¶
Disulfiram 2 221 0.79 (0.29 to 2.12) 2.34 (0.50 to 10.94) 1.05 (0.49 to 2.28) 51 (33 to 69) Low†‡§¶
Fluoxetine 1 25 1.07 (0.33 to 3.46) - 1.07 (0.33 to 3.46) 52 (25 to 78) Very low†‡§¶
Flupenthixol 1 142 2.37 (1.27 to 4.40) - 2.37 (1.27 to 4.40) 70 (56 to 81) Low†¶
Fluvoxamine 2 268 2.07 (1.09 to 3.93) 9.15 (0.40 to 209.33) 2.15 (1.30 to 3.55) 68 (57 to 78) Low†¶**
Galantamine 1 74 1.15 (0.50 to 2.64) - 1.15 (0.50 to 2.64) 54 (36 to 71) Very low†§¶
GHB 4 201 0.70 (0.34 to 1.42) 0.42 (0.11 to 1.57) 0.63 (0.36 to 1.10) 39 (27 to 52) Low†‡§
Levetiracetam 1 95 0.44 (0.19 to 1.02) - 0.44 (0.19 to 1.02) 31 (16 to 50) Very low†§¶
Lisuride 1 57 1.70 (0.57 to 5.10) - 1.70 (0.57 to 5.10) 63 (36 to 84) Very low†§¶
Lithium 1 28 1.08 (0.35 to 3.36) - 1.08 (0.35 to 3.36) 52 (26 to 77) Very low†§¶
Modafinil 1 41 1.28 (0.49 to 3.30) - 1.28 (0.49 to 3.30) 56 (33 to 77) Very low†§¶
Naltrexone 17 878 0.77 (0.49 to 1.20) 0.57 (0.27 to 1.17) 0.70 (0.50 to 0.98) 41 (33 to 50) Moderate†§
Nefazodone 1 50 1.63 (0.63 to 4.23) - 1.63 (0.63 to 4.23) 62 (39 to 81) Very low†‡§¶
Oxcarbazepine 2 72 - 0.54 (0.20 to 1.45) 0.54 (0.20 to 1.45) 35 (17 to 59) Low†§¶
Pregabalin 1 31 - 0.31 (0.07 to 1.31) 0.31 (0.07 to 1.31) 24 (7 to 57) Low†§¶
Quetiapine 1 29 0.78 (0.22 to 2.74) - 0.78 (0.22 to 2.74) 44 (18 to 73) Low†§¶
Tianeptine 1 170 1.60 (0.92 to 2.80) - 1.60 (0.92 to 2.80) 62 (48 to 74) Low†§¶
Tiapride 2 187 0.76 (0.43 to 1.33) - 0.76 (0.43 to 1.33) 43 (30 to 57) Moderate§
Topiramate 3 194 0.42 (0.16 to 1.10) 0.47 (0.19 to 1.21) 0.45 (0.24 to 0.83) 31 (19 to 45) Low†‡§¶
Trazodone 1 88 0.96 (0.41 to 2.22) - 0.96 (0.41 to 2.22) 49 (29 to 69) Very low†‡§¶
combined interventions
Placebo+CBT 1 50 1.00 (0.40 to 2.49) - 1.00 (0.40 to 2.49) 50 (29 to 71) Very low†‡§¶
Nefazodone+CBT 1 53 1.09 (0.44 to 2.70) - 1.09 (0.44 to 2.70) 52 (31 to 73) Very low†‡§¶
Acamprosate+nurse visit 1 50 - 0.21 (0.07 to 0.57) 0.21 (0.07 to 0.57) 17 (7 to 37) Low†§¶
Acamprosate+NXT 1 40 0.18 (0.06 to 0.53) 0.81 (0.17 to 3.80) 0.30 (0.13 to 0.67) 23 (12 to 40) Moderate†¶**
GHB+EST 1 12 - 0.99 (0.03 to 37.75) 0.99 (0.03 to 37.75) 50 (3 to 97) Very low†§¶
GHB+NTX 1 18 - 0.64 (0.13 to 3.13) 0.64 (0.13 to 3.13) 39 (12 to 76) Very low†‡§¶
NTX+EST 1 12 - 0.99 (0.03 to 37.75) 0.99 (0.03 to 37.75) 50 (3 to 97) Very low†§¶
NTX+GHB+EST 1 12 - 0.99 (0.03 to 37.75) 0.99 (0.03 to 37.75) 50 (3 to 97) Very low†§¶
A-CHESS=Addiction-Comprehensive Health Enhancement Support System; CBT=cognitive behavioural therapy; MET=motivational enhancement therapy; GHB=sodium salt of gamma 
hydroxybutyric acid (sodium oxybate); EST=escitalopram; NTX=naltrexone.
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such as disulfiram, for detoxified, alcohol dependent 
patients in UK primary care settings should lead to 
the generation of better evidence from high quality 
pragmatic randomised trials.
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